[1] Nagar S,Aschebrook-Kilfoy b,Kaplan EL,et al.Age of diagnosing physician impacts the incidence of thyroid cancer in a population[J].Cancer Cause Control,2014,25(12):1627-1634.
[2] Tang C,Yang L,Wang N,et al.High expression of GPER1,EGFR and CXCR1 is associated with lymph node metastasis in papillary thyroid carcinoma[J].Int J Clin Exp Pathol,2014,7(6):3213-3223.
[3] Davies L,Welch HG.Current Thymid Cancer Trends in the United States[J].JAMA Otolaryngol Head Neck Surg,2014,140(4):317-322.
[4] Liu Z,Xun X,Wang Y,et al.MRI and ultrasonography detection of cervical lymph node metastases in differentiated thyroid carcinoma before reoperation[J].Am J Transl Res,2014,6(2):147-154.
[5] Huang DP,Ye XH,Xiang YQ,et al.Thymectomy in central lymph node dissection for papillary thyroid cancer[J].Int J Clin Exp Med,2014,7(4):1135-1139.
[6] Montero PH,Ibrahimpasic T,Nixon IJ,et al.Thyroid metastasectomy[J].J Surg Oncol,2014,109(1):36-41.
[7] Cho SY,Lee TH,Ku YH,et al.Central lymph node metastasis in papillary microcarcinoma can be stratified according to the number,the size of metastatic foci,and the presence of desmoplasia[J].Surgery,2014,157(1):111-118.
[8] Liu FH,Kuo SF,Hsueh C,et al.Postoperative recurrence of papillary thyroid carcinoma with lymph node metastasis[J].Surg Oncol,2015,112(2):149-154.
[9] 徐亦熊,李学明,俞建平.BRAF基因突变和Ki-67蛋白表达与甲状腺乳头状癌的关系[J].南昌大学学报:医学版,2014,54(10):12-14.
[10] Jia Y,Yu Y,Li X,et al.Diagnostic value of BRAF(V600E) in difficult-to-diagnose thyroid nodules using fine-needle aspiration:systematic review and meta-analysis[J].Diagn Cytopathol,2014,42(1):94-101.
[11] Gerdes J,Schwab U,Lemke H,et al.Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation[J].Int J Cancer,1983,31(1):13-20.
[12] Duchrow M,Schluter C,Wohlenberg C,et al.Molecular characterization of the gene locus of the human cell proliferation-associated nuclear protein defined by monoclonal antibody Ki67[J].Cell Prolif,1996,29(1):1-12.
[13] 李刚强,濮亚斌.CD147和Ki-67在甲状腺乳头状癌中的表达及意义[J].现代肿瘤医学,2015(13):1818-1820.
[14] Pillai K,Pourgholami MH,Chua TC,et al.Prognostic significance of Ki67 expression in malignant peritoneal mesothelioma[J].Am J Clin Oncol,2015,38(4):388-394.
[15] 郭民英,邢永川,陈卫伶,等.Bcl-2、p53和Ki-67在甲状腺癌中的表达及其临床意义的研究[J].现代肿瘤医学,2014,22(6):1294-1297.
[16] Koc N,Sahin D,Ayas S.Reevaluation of negative cone biopsy results after a positive cervical biopsy finding[J].Low Genit Tract Dis,2013,17(2):154-159.
[17] Denkert C,Loibl S,Muller BM,et al.Ki-67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies:a translational investigation in the neoadjuvant GeparTrio trial[J].Ann Oncol,2013,24(11):2786-2793.
[18] Ahn HK,Jung M,Ha SY,et al.Clinical significance of Ki-67 and p53 expression in curatively resected non-small cell lung cancer[J].Tumor Biol,2014,35(6):5735-5740.
[19] Pervez S,Haroon S,Awan D.Ki-67 Labeling indices in ‘Classic’ versus ‘Blastoid’ mantle cell lymphomas-proposed cutoff values for routine diagnostic workup[J].Asian Pac J Cancer P,2015,16(15):6591-6594.
[20] Aiad H A,Bashandy MA,Abdou AG,et al.Significance of AgNORs and Ki-67 proliferative markers in differential diagnosis of thyroid lesions[J].Pathol Oncol Res,2013,19(2):167.
[21] Pujani M,Arora B,Pujani M,et al.Role of Ki-67 as a proliferative marker in lesions of thyroid[J].Indian J Cancer,2010,47(3):304-307.
[22] Song Q,Wang D,Yi L,et al.Diagnostic significance of CK19,TG,Ki67 and galectin-3 expression for papillary thyroid carcinoma in the northeastern region of China[J].Diagn Pathol,2011,6(1):126.
[23] Ranjbari N,Rahin F.The Ki-67/MIB-1 index level and recurrence of PTC[J].Med Hypotheses,2013,80(3):311-314.
[24] 万汉锋,张彬,王勇,等.甲状腺结节BRAF V600E突变检测的临床意义[J].中华耳鼻咽喉头颈外科杂志,2014,49(6):468-472.
[25] Ball DW,Jin N,Xue P,et al.Trametinib with and without pazopanib has potent preclinical activity in thyroid cancer[J].Int J Endo Oncol,2015,2(2):135-142.
[26] Galrgo A,Sodr6 A,Camargo R,et al.Methylation levels of sodiumiodide sympoger(NIS) promoter in benign and malignant thyroid tumors with reduced NIS expression[J].Endocrine,2013,43(1):225-229.
[27] Riescoeizaguirre G,Rodríguez I,De IVA,et al.The BRAFV600E oncogene induces transforming growth factor beta secretion leading to sodium iodide symporter repression and increased malignancy in thyroid cancer[J].Cancer Res,2009,69(21):8317-8325.
[28] Xing M,Alzahrani AS,Carson KA,et al.Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer[J].JAMA,2013,309(14):1493-1501.
[29] Li F,Chen G,Sheng C,et al.BRAFV600E mutation in papillary thyroid microcarcinoma:a meta-analysis[J].Endocr Relat Cancer,2015,22(2):159-168.
[30] Oh WJ,Lee YS,Cho U,et al.Classic papillary thyroid carcinoma with tall cell features and tall cell variant have similar clinicopathologic features[J].Korean J Pathol,2014,48(3):201-208.
[31] Pyo JS,Sohn JH,Kang G.BRAF immunohistochemistry using clone VE1 is strongly concordant with BRAF V600E mutation test in papillary thyroid carcinoma[J].Endocr Pathol,2015,36(3):211-217.
[32] Zhang B,Liu S,Zhang Z,et al.Analysis of BRAF (V600E) mutation and DNA methylation improves the diagnostics of thyroid fine needle aspiration biopsies[J].Diagn Pathol,2014(9):45.
[33] Adeniran AJ,Theoharis C,Hui P,et al.Reflex BRAF testing in thyroid fine-needle aspiration biopsy with equivocal and positive interpretation:a prospective study[J].Thyroid,2011,21(7):717-723.
[34] Xing M,Alzahrani AS,Carson KA,et al.Association between BRAF V600E mutation and recurrence of papillary thyroid cancer[J].Clini Oncol,2015,33(1):42-50.
[35] Puxeddu E,Filetti S. BRAF mutation assessment in papillary thyroid cancer:Are we ready to use it in clinical practice?[J].Endocrine,2014,45(3):341-343.
[36] Borrelli N,Clara Ugolini MD,Giannini R,et al.Role of gene expression profiling in defining indeterminate thyroid nodules in addition to BRAF analysis[J].Cancer Cytopathol,2016,124(5):340-349.